You are here
DENGUE VACCINE DEVELOPMENT
Award Information
Agency: Department of Defense
Branch: Army
Contract: N/A
Agency Tracking Number: 3977
Amount:
$553,000.00
Phase:
Phase II
Program:
SBIR
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Timeline
Solicitation Year:
N/A
Award Year:
1988
Award Start Date (Proposal Award Date):
N/A
Award End Date (Contract End Date):
N/A
Small Business Information
99-193 Aiea Heights Dr
Aiea, HI
96701
United States
DUNS:
N/A
HUBZone Owned:
No
Woman Owned:
No
Socially and Economically Disadvantaged:
No
Principal Investigator
Name: Morton Mandel
Phone: (808) 487-5565
Phone: (808) 487-5565
Business Contact
Phone: () -
Research Institution
N/A
Abstract
THE ULTIMATE OBJECTIVE OF THIS PROJECT IS THE PRODUCTION OF A DENGUE VACCINE. THE FOUR DENGUE VIRUSES (SEROTYPES) AS A GROUP ARE BY FAR THE MOST IMPORTANT VIRUSES TRANSMITTED TO MAN BY ARTHROPODS AND IN TERMS OF GLOBAL MORBIDITY ARE RESPONSIBLE FOR SEVERAL HUNDRED THOUSAND TO SEVERAL MILLION CASES ANNUALLY. IN PHASE I RANDOM FRAGMENTS OF THE DENGUE VIRUS 2 (RNA) GENOME WILL BE CLONED INTO A BACTERIAL EXPRESSION VECTOR. THESE RANDOMLY GENERATED FRAGMENTS WILL BE PRODUCED IN TWO WAYS TO ENSURE COMPLETE COVERAGE OF THE RNA GENOME.
* Information listed above is at the time of submission. *